Transanal Irrigation for the Management of LARS

Launched by JEWISH GENERAL HOSPITAL · Aug 10, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how a treatment called Transanal Irrigation (TAI) can help improve the quality of life for people who have Low Anterior Resection Syndrome (LARS) after surviving rectal cancer. LARS can cause various bowel issues, and the trial aims to see if TAI, which is a method of flushing out the bowel, can reduce these symptoms and make patients feel better overall. Participants in the study will learn how to use TAI through an online platform and will receive virtual support from nursing staff.

To be eligible for this trial, participants should be adults aged 65 to 74 who have had surgery for rectal cancer and have been experiencing significant bowel symptoms (with a LARS score over 20) for at least six months after their treatment. Those who can access the internet and communicate in English or French can join. Throughout the trial, participants can expect support while they learn and try this new treatment, which may help doctors better manage LARS in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Low anterior resection by a laparoscopic, robotic, transanal total mesorectal excision, or open approach with (or without) creation of a diverting loop ileostomy for the treatment of rectal cancer, advanced adenoma or dysplasia And
• • have had their ileostomy closed (if applicable) And
• • completed treatment at least 6 months ago (including ileostomy closure) And
• • LARS score \> 20 points
• Exclusion Criteria:
• • Inability to provide informed consent, including fluency in English or French language
• • unable to access the internet,
• • presence of an ostomy,
• • no active or ongoing treatment
• • anastomotic stricture, sinus or any other ongoing anastomotic complications.